{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:43:18Z","timestamp":1791492198008,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012729","name":"Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University","doi-asserted-by":"publisher","award":["1 TR000457"],"award-info":[{"award-number":["1 TR000457"]}],"id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ekir.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T20:04:13Z","timestamp":1521403453000},"page":"861-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Bortezomib for Reduction of Proteinuria in\u00a0IgA Nephropathy"],"prefix":"10.1016","volume":"3","author":[{"given":"Choli","family":"Hartono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Serur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya V.","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangamani","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2018.03.001_bib1","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"64","author":"D\u2019Amico","year":"1987","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.ekir.2018.03.001_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2018.03.001_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/ajkd.2000.8966","article-title":"Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors","volume":"36","author":"D\u2019Amico","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2018.03.001_bib6","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.2215\/CJN.04600511","article-title":"Profiling of autoantibodies in IgA nephropathy, an integrative antibiomics approach","volume":"6","author":"Sigdel","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.03.001_bib8","first-page":"629","article-title":"IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1","volume":"118","author":"Suzuki","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2018.03.001_bib9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4049\/jimmunol.165.3.1387","article-title":"Increased frequency of surface IgA-positive plasma cells in the intestinal lamina propria and decreased IgA excretion in hyper IgA (HIGA) mice, a murine model of IgA nephropathy with hyperserum IgA","volume":"165","author":"Kamata","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2018.03.001_bib10","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A\u00a0Phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.03.001_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem Biol"},{"key":"10.1016\/j.ekir.2018.03.001_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2018.03.001_bib13","first-page":"1","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"8","author":"Perry","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/ndt\/gfm351","article-title":"IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare\u00a0coincidence","volume":"22","author":"Forslund","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2018.03.001_bib15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MNH.0000000000000336","article-title":"An update on the treatment of IgA nephropathy","volume":"26","author":"Barbour","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2018.03.001_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nehropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.03.001_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2018.03.001_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00467-012-2294-6","article-title":"Spontaneous remission in children with IgA nephropathy","volume":"28","author":"Shima","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfq559","article-title":"Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy","volume":"26","author":"Han","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2018.03.001_bib22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41598-017-01223-3","article-title":"Tubular atrophy\/interstitial fibrosis scores of Oxford classification combined with proteinuria level at biopsy provides earlier risk prediction in IgA nephropathy","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2018.03.001_bib23","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024918300469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024918300469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:21:24Z","timestamp":1762831284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024918300469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2468024918300469"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2018.03.001","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib for Reduction of Proteinuria in\u00a0IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}